Analysts: Teva’s Outlook Gradually Improving and 3 Other Research Notes to Check Out

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Teva (NYSE:TEVA): After meeting with Teva line managers, Bernstein thinks the company will be able to reduce its costs by close to the promised $1.75 billion. The firm believes the company’s respiratory drugs look solid, and it keeps a $47 price target and an Outperform rating on the shares.

TEVA-20131007

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business